{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:47:26Z","timestamp":1789732046989,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA015083 and U01CA069912 grants"],"award-info":[{"award-number":["P30CA015083 and U01CA069912 grants"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10637-020-00936-z","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T23:06:11Z","timestamp":1587683171000},"page":"1755-1762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors"],"prefix":"10.1007","volume":"38","author":[{"given":"Mojun","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian R.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace K.","family":"Dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Croghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Glockner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorelei J.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina D.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"issue":"Suppl 1","key":"936_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.5-suppl_1-3","volume":"5","author":"G McMahon","year":"2000","unstructured":"McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5(Suppl 1):3\u201310","journal-title":"Oncologist"},{"issue":"3","key":"936_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/cbic.200400305","volume":"6","author":"H Hess-Stumpp","year":"2005","unstructured":"Hess-Stumpp H, Haberey M, Thierauch KH (2005) PTK 787\/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 6(3):550\u2013557. https:\/\/doi.org\/10.1002\/cbic.200400305","journal-title":"Chembiochem"},{"issue":"8","key":"936_CR3","first-page":"2178","volume":"60","author":"JM Wood","year":"2000","unstructured":"Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F (2000) PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60(8):2178\u20132189","journal-title":"Cancer Res"},{"issue":"14","key":"936_CR4","first-page":"4015","volume":"62","author":"J Drevs","year":"2002","unstructured":"Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, Marme D (2002) PTK787\/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62(14):4015\u20134022","journal-title":"Cancer Res"},{"issue":"15","key":"936_CR5","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/j.ejca.2010.07.014","volume":"46","author":"N Cook","year":"2010","unstructured":"Cook N, Basu B, Biswas S, Kareclas P, Mann C, Palmer C, Thomas A, Nicholson S, Morgan B, Lomas D, Sirohi B, Mander AP, Middleton M, Corrie PG (2010) A phase 2 study of vatalanib in metastatic melanoma patients. Eur J Cancer (Oxford, England : 1990) 46(15):2671\u20132673. https:\/\/doi.org\/10.1016\/j.ejca.2010.07.014","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"15","key":"936_CR6","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/jco.2010.29.4496","volume":"29","author":"JR Hecht","year":"2011","unstructured":"Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D (2011) Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29(15):1997\u20132003. https:\/\/doi.org\/10.1200\/jco.2010.29.4496","journal-title":"J Clin Oncol"},{"issue":"15","key":"936_CR7","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/jco.2010.29.5436","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, Bajetta E, Valle J, Kohne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lebwohl D, Meinhardt G, Laurent D, Lin E (2011) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787\/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29(15):2004\u20132010. https:\/\/doi.org\/10.1200\/jco.2010.29.5436","journal-title":"J Clin Oncol"},{"issue":"3","key":"936_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/annonc\/mdr255","volume":"23","author":"TC Gauler","year":"2012","unstructured":"Gauler TC, Besse B, Mauguen A, Meric JB, Gounant V, Fischer B, Overbeck TR, Krissel H, Laurent D, Tiainen M, Commo F, Soria JC, Eberhardt WE (2012) Phase II trial of PTK787\/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB\/IV non-small-cell lung cancer (NSCLC). Ann Oncol 23(3):678\u2013687. https:\/\/doi.org\/10.1093\/annonc\/mdr255","journal-title":"Ann Oncol"},{"issue":"4","key":"936_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.clgc.2013.11.020","volume":"12","author":"RL Bitting","year":"2014","unstructured":"Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ (2014) A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 12(4):241\u2013250. https:\/\/doi.org\/10.1016\/j.clgc.2013.11.020","journal-title":"Clin Genitourin Cancer"},{"issue":"15","key":"936_CR10","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/jco.2010.33.2429","volume":"29","author":"AF Sobrero","year":"2011","unstructured":"Sobrero AF, Bruzzi P (2011) Vatalanib in advanced colorectal Cancer: two studies with identical results. J Clin Oncol 29(15):1938\u20131940. https:\/\/doi.org\/10.1200\/jco.2010.33.2429","journal-title":"J Clin Oncol"},{"key":"936_CR11","unstructured":"Everolimus. (2019) https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/CS\/A7D823\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/A1C902\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/evidencexpert.DoIntegratedSearch?SearchTerm=everolimus&UserSearchTerm=everolimus&SearchFilter=filterNone&navitem=searchALL#. Accessed 28 Oct 2019"},{"issue":"21","key":"936_CR12","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1200\/jco.2003.08.092","volume":"21","author":"B Morgan","year":"2003","unstructured":"Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787\/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21(21):3955\u20133964. https:\/\/doi.org\/10.1200\/jco.2003.08.092","journal-title":"J Clin Oncol"},{"issue":"18","key":"936_CR13","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/jco.2005.09.034","volume":"23","author":"AL Thomas","year":"2005","unstructured":"Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP (2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787\/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23(18):4162\u20134171. https:\/\/doi.org\/10.1200\/jco.2005.09.034","journal-title":"J Clin Oncol"},{"issue":"13","key":"936_CR14","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1200\/jco.2009.26.3152","volume":"28","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28(13):2131\u20132136. https:\/\/doi.org\/10.1200\/jco.2009.26.3152","journal-title":"J Clin Oncol"},{"issue":"2","key":"936_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00280-010-1507-6","volume":"67","author":"KE Bullock","year":"2011","unstructured":"Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, Bendell JC (2011) A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol 67(2):465\u2013474. https:\/\/doi.org\/10.1007\/s00280-010-1507-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"936_CR16","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.18632\/oncotarget.1834","volume":"5","author":"SA Piha-Paul","year":"2014","unstructured":"Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R (2014) Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget 5(7):1846\u20131855. https:\/\/doi.org\/10.18632\/oncotarget.1834","journal-title":"Oncotarget"},{"issue":"2","key":"936_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","volume":"129","author":"KC Shih","year":"2016","unstructured":"Shih KC, Chowdhary S, Rosenblatt P, Weir AB 3rd, Shepard GC, Williams JT, Shastry M, Burris HA 3rd, Hainsworth JD (2016) A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neuro-Oncol 129(2):281\u2013288. https:\/\/doi.org\/10.1007\/s11060-016-2172-3","journal-title":"J Neuro-Oncol"},{"issue":"32","key":"936_CR18","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1200\/jco.2016.67.9084","volume":"34","author":"MH Voss","year":"2016","unstructured":"Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, Hsieh JJ, Motzer RJ, Feldman DR (2016) Phase II trial and correlative genomic analysis of Everolimus plus Bevacizumab in advanced non-clear cell renal cell carcinoma. J Clin Oncol 34(32):3846\u20133853. https:\/\/doi.org\/10.1200\/jco.2016.67.9084","journal-title":"J Clin Oncol"},{"issue":"2","key":"936_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ygyno.2018.08.027","volume":"151","author":"WP Tew","year":"2018","unstructured":"Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA (2018) Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: an NRG oncology\/gynecologic oncology group study. Gynecol Oncol 151(2):257\u2013263. https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.027","journal-title":"Gynecol Oncol"},{"issue":"10022","key":"936_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/s0140-6736(15)00817-x","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet (London, England) 387(10022):968\u2013977. https:\/\/doi.org\/10.1016\/s0140-6736(15)00817-x","journal-title":"Lancet (London, England)"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00936-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00936-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00936-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:48:42Z","timestamp":1678510122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00936-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["936"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00936-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no potential conflicts of interest or competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the institutional review board of Mayo Clinic.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}